TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00248170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg tablets
Study: NCT02333487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 5 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 5 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 5 mg tablets for oral administration
Study: NCT02879110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet is composed of starch.
Study: NCT02377921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aceneuramic acid extended-release (Ace-ER)
Description: tablets for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets for oral use
Study: NCT02029781

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LAPP score
Description: Use of the LAPP score during a diagnostic laparoscopy.
Study: NCT02116699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oropharyngeal mother's milk
Description: Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oropharyngeal sterile water
Description: Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
Study: NCT02602834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interval training
Description: 4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interval training
Description: 4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate exercise
Description: 30 minutes (moderate intensity) aerobic exercise on treadmill without rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate exercise
Description: 30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
Study: NCT02758249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: patients are anesthetized by using sevoflurane inhalation
Study: NCT04618614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS 1 mA to S1
Description: Anodal high definition transcranial direct current stimulation of the right primary somatosensory cortex with an intensity of 1 mA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS 1 mA to M1
Description: Anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1 mA

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Sham stimulation of the right primary somatosensory cortex
Study: NCT01350804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIN457
Description: AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
Study: NCT02758249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: patients are anesthetized by using propofol infusion
Study: NCT03813693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: towels impregnated with 2% chlorhexidine gluconate
Description: The first TICHG should be used on the neck, chest and abdomen; The second TICHG should be used on the right upper limb, start at the shoulder; The third TICHG was intended for the upper left limb; The fourth TICHG should be used on the neck and chest; The fifth TICHG was for the right lower limb; The sixth TICHG should be used on the lower left limb.~2) Time of application: use six TICHGs the night before surgery and the six remaining on the morning of surgery.~3) After the hygiene of each member, discard the TICHG. After use of TICHG, allow the product to dry on the skin. Do not use bath towels to dry yourself and wear clean clothes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gluconate 2% liquid
Description: Spread the product on the skin during the bath and massage for 3 minutes, so that it is distributed equally to all parts of the body (except the face, hair and intimate area). Then rinse with water and dry with a clean, dry towel, and wear clean clothes.
Study: NCT00616174

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Active warming with Bair Hugger blanket
Description: Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
Study: NCT00646620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol (Advair Diskus)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol (Ventolin)
Study: NCT00706667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferinject ®
Description: iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject ®
Description: iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject ®
Description: iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
Study: NCT02364947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene hydrochloride
Description: As-needed; tablets, orally
Study: NCT02294955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disopyramide
Description: Dosage orally 250-375 mg twice Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronedarone
Description: Dosage orally 400 mg twice daily
Study: NCT02364947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene hydrochloride
Description: As-needed; tablets, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As-needed; tablets, orally
Study: NCT01850745

Intervention type: OTHER
Intervention: Multidisciplinary support program
Description: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.

Intervention type: OTHER
Intervention: Multidisciplinary support program
Description: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.
Study: NCT01767194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study: NCT01350804

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
Study: NCT00461747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VBMCP/VBAD/Velcade
Description: VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20.
Study: NCT01767194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT03780556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lornoxicam and mepridine
Description: compare the effect of each to control pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lornoxicam and mepridine
Description: compare the effect of each to control pain
Study: NCT02163304

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Sweetner

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tasteless Solution
Study: NCT01586156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be taken twice daily for 6 months
Study: NCT01676402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza DNA vaccine
Description: VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
Study: NCT00461747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide/Dexamethasone
Description: Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity \< grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days
Study: NCT02445209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mDCF
Description: combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
Study: NCT02433938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tibial nerve stimulation
Description: patients underwent a three days postoperative transcutaneous tibial nerve stimulation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham tibial nerve stimulation
Description: patients did not undergo a postoperative transcutaneous tibial nerve stimulation
Study: NCT03627702

Intervention type: RADIATION
Intervention: Irradiated VIP (Visible Incoherent Polarized)
Description: 20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
Study: NCT00461747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade/Thalidomide/Dexamethasone
Description: Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is \< grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days
Study: NCT00976625

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aortic Valve Replacement
Description: Surgical valve replacement of the aorta
Study: NCT02206672

Intervention type: OTHER
Group type: OTHER
Intervention: Micro reinjection of autologus adipose tissue
Study: NCT04257435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychological Group Treatment
Description: Positive psychological group treatment will involve engagement in traditional behavioral health treatment, as well as a group treatment focusing on previously researched exercises that have been demonstrated to relate to reduced depression and increased positive emotionality (Seligman, Rashid, Parks, et al., 2005; Seligman, Rashid, \& Parks, 2006; Rashid, 2015).
Study: NCT04257435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Behavioral Health Treatment
Description: Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Behavioral Health Treatment
Description: Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).
Study: NCT02711293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART home delivery
Description: Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count \>350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been \>350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART home delivery
Description: Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count \>350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been \>350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced nutrition counseling
Description: Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced nutrition counseling
Description: Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
Study: NCT03798080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT04631003

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: dynamic functional testing
Description: First, with an arthroCT of the wrist by intraarticular injection of contrast agent, a possible scaphulonary band lesion is detected. The surgeon does not yet know the findings of the possible ligament injury at this time, but he can assess the fracture in the CT. Subsequently, a dynamic functional test of the scapholunary distance is carried out intraoperatively under investigation with the modified Watson test before and after performing the osteosynthesis. For this purpose, the wrist is intraoperatively brought under pull on the thumb from a radial abduction into an ulnarabduction. In the presence of a scapholunary instability, a change in the distance of the scapholunary joint gap is shown here under illumination. Now the surgeon receives the finding of the Arthro-CT regarding an existing ligament injury. If necessary, this is treated in the same anaesthetic with a band seam and ossary transfixation.
Study: NCT03210129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: the patients of the motivational interviewing group will receive 12 motivational interviewing sessions within 12 weeks: 2 face-to-face sessions and 10 phone call sessions. The first and the seventh motivational interviewing sessions will be face-to-face sessions. An intervention is considered valid if a minimum of 10 sessions has been completed. The face-to-face motivational interviewing sessions will be administered at the Luxembourg Institute of Health (Strassen, Luxembourg). They generally last up to 30 minutes, while the motivational interviewing phone calls generally last up to 15 minutes. Thereby, patients in the motivational interviewing group will receive a total of approximately 3.5 hours of contact time over a period of 12 weeks.~Motivational interviewing techniques will explore self-assessed confidence, ambivalence, and personal values concerning changes in active lifestyle.
Study: NCT01676402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza DNA vaccine
Description: VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
Study: NCT02340988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Dose IV Oritavancin Diphosphate and Warfarin
Description: Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose
Description: Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
Study: NCT04270994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol